Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes.
boolean
C0011860 (UMLS CUI [1])
Sulfonylurea | Biguanides | Thiazolidinediones | Sulfonylurea Dose Maximum Maintenance | Sulfonylurea Dose Maximum Approved | alpha-Glucosidase Inhibitors To be stopped | Acarbose To be stopped | Voglibose To be stopped | Miglitol To be stopped | Meglitinide Derivative To be stopped | Mitiglinide To be stopped | Nateglinide To be stopped
Item
has been treated by sulfonylurea (su) alone, su and biguanide, or su and thiazolidinedione for at least 90 days prior to study start. in a patient receiving su alone, the dose must be within the dose range from maximum maintenance dose to maximum approved dose. the patients with concomitant use of alpha glucosidase inhibitors (acarbose, voglibose or miglitol) or meglitinide derivatives (mitiglinide or nateglinide) can be included in this study, but these drugs must be discontinued at study start.
boolean
C0038766 (UMLS CUI [1])
C0005382 (UMLS CUI [2])
C1257987 (UMLS CUI [3])
C0038766 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0806909 (UMLS CUI [4,3])
C0024501 (UMLS CUI [4,4])
C0038766 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0806909 (UMLS CUI [5,3])
C0205540 (UMLS CUI [5,4])
C1299007 (UMLS CUI [6,1])
C1272691 (UMLS CUI [6,2])
C0050393 (UMLS CUI [7,1])
C1272691 (UMLS CUI [7,2])
C0532578 (UMLS CUI [8,1])
C1272691 (UMLS CUI [8,2])
C0066535 (UMLS CUI [9,1])
C1272691 (UMLS CUI [9,2])
C0065880 (UMLS CUI [10,1])
C1527240 (UMLS CUI [10,2])
C1272691 (UMLS CUI [10,3])
C0906166 (UMLS CUI [11,1])
C1272691 (UMLS CUI [11,2])
C0903898 (UMLS CUI [12,1])
C1272691 (UMLS CUI [12,2])
Hemoglobin A1c measurement
Item
have hba1c 7.0% to 10% at study start.
boolean
C0474680 (UMLS CUI [1])
Body Weight
Item
have a body weight >=50 kg.
boolean
C0005910 (UMLS CUI [1])
Off-Label Treatment
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C1096117 (UMLS CUI [1])
Study Subject Participation Status | exenatide | GLP-1 analogues
Item
have participated in this study previously or any other study using exenatide or glucagon-like peptide-1 (glp-1) analogs within the last 90 days.
boolean
C2348568 (UMLS CUI [1])
C0167117 (UMLS CUI [2])
C4301632 (UMLS CUI [3])
Insulin Exogenous
Item
have been treated with any exogenous insulin within 90 days before study start.
boolean
C0021641 (UMLS CUI [1,1])
C0205228 (UMLS CUI [1,2])
Pharmaceutical Preparations Affecting Gastrointestinal Motility
Item
have been continuously treated with any drug that directly affects gastrointestinal motility for more than a total of 21 days in the 90 days prior to study start.
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
Combined Modality Therapy | Sulfonylurea | Biguanides | Thiazolidinediones
Item
the combination therapy of sulfonylurea, biguanide and thiazolidinedione is not allowed.
boolean
C0009429 (UMLS CUI [1])
C0038766 (UMLS CUI [2])
C0005382 (UMLS CUI [3])
C1257987 (UMLS CUI [4])